Celea, backed by investors such as RA Capital and Leaps by Bayer, is making what it says is an improved version of Roche's Esbriet.
An article from
Celea, backed by investors such as RA Capital and Leaps by Bayer, is making what it says is an improved version of Roche’s Esbriet.
Published July 2, 2026
The biotech, which announced a $180 million raise on July 2, 2026, is one of several working on new pulmonary fibrosis drugs.
Getty Images
IPF biotech Celea gets $180M to follow paths of PureTech's Karuna, Seaport
PureTech Founded Entity Celea Therapeutics Completes $180 Million Financing to Advance Deupirfenidone as a Potential New Standard of Care to Treat Idiopathic Pulmonary Fibrosis (IPF)
Celea Therapeutics Announces $180 Million Financing to Advance Deupirfenidone as a Potential New Standard of Care to Treat Idiopathic Pulmonary Fibrosis (IPF)
BridgeBio attracts $1B in equity for new launches, but analyst smells M&A ‘dry powder’
Investors double down on Bain-backed startup
Celea has corralled $180 million to see if its twist on an approved medicine for idiopathic pulmonary fibrosis can beat the…
PureTech Founded Entity Celea Therapeutics Completes $180 Million Financing to Advance Deupirfenidone as a Potential New Standard…
Celea Therapeutics Announces $180 Million Financing to Advance Deupirfenidone as a Potential New Standard of Care to Treat…
The startup is developing a medicine that works differently than available treatments for thyroid eye disease and could benefit…
Pierre Fabre claims to now be “aligned” with U.S. regulators on the path forward for a twice-rejected treatment. Elsewhere,…
The biotechnology startup emerged from stealth with a peptide drug it claims to have the potential to reverse lung scarring in…
